Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METRETON vs METRO I.V. IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.
Metronidazole exerts its antibacterial and antiprotozoal effects by entering the microbial cell and undergoing reduction by intracellular electron transport proteins, forming reactive metabolites that interact with DNA, causing strand breakage and inhibition of nucleic acid synthesis.
Seasonal allergic conjunctivitis,Perennial allergic conjunctivitis,Other allergic ocular conditions
Treatment of intra-abdominal infections (peritonitis, intra-abdominal abscess),Treatment of bacterial vaginosis,Treatment of trichomoniasis,Treatment of amebiasis (amebic dysentery and amebic liver abscess),Treatment of skin and skin structure infections (decubitus ulcers, infected wounds),Treatment of gynecologic infections (endometritis, tubo-ovarian abscess),Treatment of central nervous system infections (meningitis, brain abscess),Treatment of septicemia and endocarditis,Off-label: Perioperative prophylaxis for colorectal surgery,Off-label: Treatment of Helicobacter pylori infection (combined with other agents),Off-label: Crohn's disease (perianal fistulas)
1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.
IV: 500 mg every 6 h or 1 g every 12 h. For severe infections: 750 mg every 6 h. Max 4 g/day.
Terminal elimination half-life is 24-36 hours; increased in renal impairment (up to 60 hours in anuria)
8 hours (6-12 hours) in adults; prolonged in hepatic impairment
Not extensively metabolized; primarily excreted unchanged in urine.
Hepatic metabolism via oxidation and glucuronidation, primarily by CYP450 enzymes (CYP2A6, CYP3A4). The major metabolites are hydroxymetronidazole and metronidazole glucuronide.
Renal (80-90% as unchanged drug and metabolites), biliary/fecal (10-20%)
Renal (60-80% as unchanged drug), fecal (6-15%), biliary (small amount)
75-85% bound to albumin and alpha-1-acid glycoprotein
<20% bound to plasma proteins
0.5-1.0 L/kg; indicates moderate tissue distribution
0.25-0.85 L/kg; indicates wide distribution into tissues including CSF
Oral: 50-70% (first-pass metabolism); Intramuscular: 80-100%
100% intravenous
Cr Cl 10-50 m L/min: administer every 12 hours; Cr Cl <10 m L/min: administer every 12-18 hours or consider dose reduction by 50%.
Cr Cl 10-50 m L/min: 500 mg every 12 h. Cr Cl <10 m L/min: 500 mg every 24 h. Hemodialysis: dose after dialysis.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce dose by 75%.
Child-Pugh A: no adjustment. Child-Pugh B or C: reduce dose by 50% (e.g., 500 mg every 12 h).
0.5-1 mg/kg intramuscularly or intravenously every 6-8 hours; maximum 25 mg per dose for children <40 kg.
Neonates (GA <34 wk): 7.5 mg/kg every 12 h; (GA ≥34 wk): 7.5 mg/kg every 8 h. Infants/children: 10 mg/kg every 6-8 h. Max 4 g/day.
Start at lower end of dosing range (e.g., 0.5-1 mg/kg) with extended intervals (every 8-12 hours) due to decreased renal function and increased sensitivity.
Cr Cl 10-50 m L/min: 500 mg every 12 h. Cr Cl <10 m L/min: 500 mg every 24 h. Monitor for neurotoxicity.
None
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Unnecessary use should be avoided.
Do not inject; for ophthalmic use only.,May cause transient burning or stinging.,Use with caution in patients with narrow-angle glaucoma.
May cause seizures and peripheral neuropathy; discontinue if neurologic symptoms occur.,Use caution in patients with central nervous system disorders.,Blood dyscrasias: Use with caution in patients with history of or current blood dyscrasias.,Hepatic impairment: Dose adjustment may be required.,Carcinogenicity: Avoid prolonged or unnecessary use.,Drug interactions: Potentiation of anticoagulant effect of warfarin; disulfiram-like reaction with alcohol.,Prolonged QT interval: Use with caution with QT-prolonging agents.,Superinfection: May cause overgrowth of Clostridioides difficile.
Hypersensitivity to any component of the formulation
Hypersensitivity to metronidazole or other nitroimidazole derivatives,First trimester of pregnancy (relative contraindication; use only if clearly needed),Breastfeeding (manufacturer recommends discontinuation of nursing or drug, but AAP considers compatible),Use with disulfiram (within 2 weeks of disulfiram administration),Use with alcohol or propylene glycol-containing products (due to disulfiram-like reaction)
Avoid excessive alcohol intake (increases risk of lactic acidosis). No specific food restrictions, but consistent carbohydrate intake is recommended to prevent hypoglycemia. Grapefruit may increase metformin levels (use caution).
Avoid alcohol and any foods or beverages containing alcohol (e.g., beer, wine, liquor, some vinegars, certain desserts) for 48 hours after last dose. No other significant food interactions.
Pregnancy Category C: Fetal risk cannot be ruled out. First trimester: Increased risk of cleft palate and cardiac malformations due to corticosteroid component (prednisolone). Second and third trimesters: Potential for intrauterine growth restriction, adrenal suppression in neonate. Avoid use unless benefit outweighs risk.
Metronidazole crosses the placenta. In the first trimester, data are conflicting but meta-analyses show no significant increase in major malformations; however, some studies suggest a possible small risk of cleft palate. The CDC and FDA consider it contraindicated in the first trimester unless clearly needed. In the second and third trimesters, it is generally considered safe, but caution is advised near term due to potential neonatal accumulation.
Prednisolone and chlorpheniramine (components of METRETON) are excreted into breast milk. M/P ratio for prednisolone is approximately 0.5-0.7. Low risk at maternal doses <20 mg/day; higher doses may cause infant adrenal suppression or growth delay. Consider alternative antihistamine with lower excretion.
Metronidazole is excreted into breast milk with milk-to-plasma ratio of approximately 0.6-1.0. Peak milk concentrations occur 2-4 hours after dose. The American Academy of Pediatrics considers it compatible with breastfeeding, but some sources advise discarding milk for 12-24 hours after a single high dose (2 g) to reduce infant exposure. For standard dosing, benefits likely outweigh risks.
No specific dose adjustment required; use lowest effective dose for shortest duration. Pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism) may reduce efficacy of standard doses; monitor clinical response and consider dose titration. Avoid high-dose or prolonged therapy.
Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced hepatic clearance) may reduce serum concentrations of metronidazole, but the clinical significance is unclear. No dose adjustment is routinely recommended; however, for serious infections, therapeutic drug monitoring may be considered. Standard dosing (e.g., 500 mg IV every 8 hours) is typically used.
METRETON is a fixed-dose combination of metformin and sitagliptin. Use with caution in patients with renal impairment (check e GFR before initiation; contraindicated if e GFR <30 m L/min/1.73 m²). Monitor for lactic acidosis, especially in hypoxic states or hepatic impairment. Discontinue temporarily before iodinated contrast imaging and for surgery. Assess for pancreatitis (discontinue if suspected). Do not use in type 1 diabetes or diabetic ketoacidosis. Dose adjustment of sitagliptin needed if e GFR 30-45 m L/min/1.73 m² (50 mg daily).
Metronidazole IV exhibits excellent bioavailability; oral and IV dosing are equivalent. Avoid ethanol-containing medications or diet due to disulfiram-like reaction. Monitor for peripheral neuropathy with prolonged use. Adjust dose in severe hepatic impairment (Child-Pugh C).
Take with meals to reduce gastrointestinal side effects.,Do not drink excessive alcohol while taking this medication.,Monitor for symptoms of lactic acidosis (unusual tiredness, muscle pain, trouble breathing, stomach pain) and pancreatitis (severe stomach pain, nausea, vomiting).,Inform your doctor if you become pregnant or plan to breastfeed.,Report any signs of allergic reaction (rash, hives, swelling of face/lips/throat) immediately.,Maintain adequate fluid intake, especially during illness or in hot weather.,Do not skip meals or drastically reduce carbohydrate intake without consulting your provider.
Do not consume alcohol or products containing propylene glycol during treatment and for at least 48 hours after completion.,Report any numbness, tingling, or burning in hands or feet immediately.,Complete the full course as prescribed even if symptoms improve.,May cause metallic or bitter taste; this is temporary and harmless.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METRETON vs METRO I.V. IN PLASTIC CONTAINER, answered by our medical review team.
METRETON is a Antibiotic (Nitroimidazole) that works by Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.. METRO I.V. IN PLASTIC CONTAINER is a Antibiotic (Nitroimidazole) that works by Metronidazole exerts its antibacterial and antiprotozoal effects by entering the microbial cell and undergoing reduction by intracellular electron transport proteins, forming reactive metabolites that interact with DNA, causing strand breakage and inhibition of nucleic acid synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METRETON and METRO I.V. IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Antibiotic (Nitroimidazole) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METRETON is: 1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.. The standard adult dose of METRO I.V. IN PLASTIC CONTAINER is: IV: 500 mg every 6 h or 1 g every 12 h. For severe infections: 750 mg every 6 h. Max 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METRETON and METRO I.V. IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METRETON is classified as Category C. Pregnancy Category C: Fetal risk cannot be ruled out. First trimester: Increased risk of cleft palate and cardiac malformations due to corticosteroid component (prednisolone). Seco. METRO I.V. IN PLASTIC CONTAINER is classified as Category C. Metronidazole crosses the placenta. In the first trimester, data are conflicting but meta-analyses show no significant increase in major malformations; however, some studies sugges. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.